PLM-101

MedChem Express

PLM-101

14

Research Use Only

C22H22FN5O2

407.44

PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po)[1].

FC1=CC2=C(C=C1)NC(/C2=C3NC4=CC=CC=C4C\3=N/OCCN5CCNCC5)=O

12131703